Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen’s Esketamine Gets US FDA Panel Endorsement, But With Pricing, Access And Diversion Concerns

Executive Summary

Committee overwhelmingly supports approval for treatment-resistant depression but warns that pricing and combination therapy indication could hinder patient access. Esketamine’s risks of sedation and dissociative effects, and its abuse potential, will necessitate a strict risk management strategy.

Advertisement

Related Content

Janssen’s Spravato Enters US Market With Enhanced REMS And Plans For A Monotherapy Trial
J&J Foresees Broad Insurance Coverage For Groundbreaking Spravato Nasal Spray
Sage Impresses With Second Postpartum Depression Therapy
J&J's Mixed Phase III Data For Esketamine Highlight Challenges In Resistant Depression
Allergan paying $560m for Naurex; stays quiet on rumored generics sale to Teva
KV Emerging From Bankruptcy As Makena Sales Pick Up Steam

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel